Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,124 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,545 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (885)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03251417 | Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 11 | Peking UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT04510285 | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection | terminated | Phase 2 | 1 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2023 |
| clinicaltrials |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers | terminated | N/A | 12 | Stanford UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT03818165 | Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases(AntiCEA_CART) | terminated | Phase 1 | 2 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT03582618 | CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma | terminated | Phase 2 | 12 | TaiRx, Inc.INDUSTRY | 2 | Jan 10, 2023 | clinicaltrials |
| NCT04044430 | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | terminated | Phase 1 | 2 | University of California, San FranciscoOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT05368688 | Microbiome in Colorectal Cancer Onset and Progression | terminated | — | 63 | ViomeINDUSTRY | 1 | Dec 27, 2022 | clinicaltrials |
| NCT01433016 | Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI(OBT for HCC) | terminated | Phase 2 | 20 | Meridian Bioscience, Inc.INDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT01381211 | Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)(TRACE) | terminated | Phase 2 | 72 | University Hospital, GhentOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT04642690 | Nitrates and IL-8 in Barrett's Esophagus | terminated | — | 9 | Mayo ClinicOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05291988 | A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial | terminated | N/A | 8 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT03781960 | Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | terminated | Phase 2 | 7 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05380557 | ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing(ARTEMIS) | terminated | — | 2 | Invitae CorporationINDUSTRY | 1 | Dec 7, 2022 | clinicaltrials |
| NCT04076761 | Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma(MOCHA) | terminated | Phase 2 | 8 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 1, 2022 | clinicaltrials |
| NCT04304781 | Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer | terminated | Phase 1 | 12 | Danielle Kim TurgeonOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT04400903 | Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer | terminated | — | 110 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT01167374 | Carbon Ion Radiotherapy for Hepatocellular Carcinoma(PROMETHEUS-01) | terminated | N/A | 21 | University Hospital HeidelbergOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | terminated | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma | terminated | Phase 2 | 17 | Delcath Systems Inc.INDUSTRY | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT03781778 | Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors | terminated | Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | terminated | Phase 2 | 17 | Northwestern UniversityOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT04985136 | A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) | terminated | Phase 3 | 1 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT03945799 | A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence | terminated | Phase 1 / Phase 2 | 28 | Zhejiang UniversityOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03998033 | Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma(ET-109) | terminated | Phase 1 | 2 | Eureka Therapeutics Inc.INDUSTRY | 1 | Aug 23, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | terminated | Phase 1 / Phase 2 | 2 | Silverback TherapeuticsINDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT01525069 | Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma | terminated | Phase 1 | 27 | Washington University School of MedicineOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT02446925 | Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study | terminated | N/A | 8 | Wright State UniversityOTHER | 0 | Jul 28, 2022 | clinicaltrials |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Kathy MillerOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT00746590 | Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma | terminated | Phase 2 | 1 | BTG International Inc.OTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT03402607 | Trial Comparing PLA to HIGRT (PROVE-HCC)(PROVE-HCC) | terminated | N/A | 12 | Duke UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT03012282 | CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer | terminated | N/A | 70 | University of WashingtonOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT01402908 | A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection(PATRON) | terminated | Phase 3 | 520 | Cellxpert Biotechnology Corp.INDUSTRY | 4 | Jun 23, 2022 | clinicaltrials |
| NCT00573131 | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer | terminated | Phase 2 | 137 | Boston Scientific CorporationINDUSTRY | 4 | Jun 22, 2022 | clinicaltrials |
| NCT03956940 | Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib(HELP) | terminated | N/A | 18 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment | terminated | Phase 1 | 60 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 1, 2022 | clinicaltrials |
| NCT04727541 | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer(NEOBIL) | terminated | Phase 2 | 3 | AIO-Studien-gGmbHOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT03059147 | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 7 | SignalRX Pharmaceuticals, Inc.INDUSTRY | 1 | May 18, 2022 | clinicaltrials |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | terminated | Phase 1 / Phase 2 | 20 | Apollomics (Australia) Pty. Ltd.INDUSTRY | 2 | May 6, 2022 | clinicaltrials |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 50 | Genoscience PharmaINDUSTRY | 3 | May 2, 2022 | clinicaltrials |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 140 | Polaris GroupINDUSTRY | 6 | Apr 25, 2022 | clinicaltrials |
| NCT02704130 | TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma | terminated | N/A | 8 | Wake Forest University Health SciencesOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT03707028 | A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 12 | Elevar TherapeuticsINDUSTRY | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03852836 | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images(BiliFast) | terminated | N/A | 53 | IHU StrasbourgOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03278626 | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 12 | NYU Langone HealthOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer(ILIAD) | terminated | Phase 1 | 21 | MendusINDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT03979547 | EXALT: EXercise Attenuates Liver Tumors Trial(EXALT) | terminated | N/A | 3 | Milton S. Hershey Medical CenterOTHER | 1 | Mar 9, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 1, 2023source: clinicaltrials